Abstract. Both transforming growth factor (TGF)-ß and the non-receptor tyrosine kinase Src play major roles during tumorigenesis by regulating cell growth, epithelial-to-mesenchymal transition (EMT), migration/invasion and metastasis, but little is known about the signaling crosstalk between them. To interfere with Src function in vitro and in vivo many studies have employed the pharmacologic Src inhibitors PP2 and PP1. Both agents have recently been shown to be powerful inhibitors of TGF-ß receptor type I/ALK5 and type II. As this situation prohibited any definite conclusions with respect to the relative contribution of TGF-ß vs. Src signaling, we decided to reappraise a potential role of Src in TGF-ß1-mediated cellular responses using RNA and dominant-negative (dn) interference to block Src expression and function, respectively. In TGF-ß-responsive pancreatic ductal adenocarcinoma (PDAC) cells, we show that Src is activated by TGF-ß1 and that its specific inhibition strongly attenuated basal proliferation and enhanced TGF-ß1-mediated growth arrest. However, Src inhibition was unable to impair TGF-ß1-controlled EMT as evidenced by cell morphology and regulation of the epithelial marker E-cadherin. Despite its dispensibility for TGF-ß-induced EMT, specific inhibition of Src dramatically reduced basal and TGF-ß1-induced cell migration in Panc-1 cells as measured with a novel real-time migration assay (xCELLigence DP system). Biochemically, dnSrc inhibition failed to block TGF-ß1/ALK5-induced activation of Smad2 and Smad3, but partially inhibited transcriptional activation of TGF-ß/Smad-responsive reporter genes, and effectively blocked basal and TGF-ß1-induced activation of p38 MAPK. Together, the data provide evidence for a role of Src in the regulation of basal proliferation as well as in basal and TGF-ß1-mediated cell motility but not EMT in TGF-ß-responsive pancreatic (tumor) cells.
Introduction
Src kinases are non-receptor intracellular tyrosine kinases that mediate a variety of cellular responses. The prototype member p60
Src is the product of the proto-oncogene c-Src, and is the cellular homolog of the Rous sarcoma virus transforming protein v-Src. Src kinases are involved in numerous signaling pathways controlling proliferation, migration, adhesion, and angiogenesis (1) . Src together with · V ß3 integrin promotes anchorage-independent growth and metastasis (2) and recent data have revealed that transient activation of Src by immortalized mammary epithelial cells triggered an inflammatory response that resulted in the initiation and maintenance of cellular transformation and a switch from a non-transformed to a transformed phenotype (3) . Src mediates signaling from many types of receptors including receptor tyrosine kinases (EGF-R), integrins, and G-protein-coupled receptors such as proteinase-activated receptors (PARs) (4) . Src is required for EGF-R stimulated DNA synthesis and has been reported to stimulate IGF-I-dependent cell proliferation by increasing IGF-I receptor number (5) . Moreover, overexpression of activated c-Src has been reported to stimulate migration, downregulation of E-cadherin (6) , and an increase in IL-8 expression and angiogenesis (7) . Pharmacologic Src inhibition demonstrated significant antitumor and antimetastatic activity in an orthotopic mouse model of human PDAC (8) and reverted inherent and acquired chemoresistance in pancreatic tumor cells in vitro (9, 10) and in vivo (10) .
Transforming growth factor (TGF-)ß1 is a pleiotropic growth factor that controls proliferation, cell migration, and morphological plasticity such as epithelial-to-mesenchymal transition (EMT). TGF-ß signals through two membranebound receptors designated type II (TßRII) and type I/ALK5. After being phosphorylated by TßRII on serine/threonine residues, ALK5 activates the canonical Smad pathway by phosphorylating receptor-regulated Smads (R-Smads) Smad2 and Smad3. Activated R-Smads subsequently form a complex with Smad4 (also known as DPC4) which moves into the nucleus to regulate the transcriptional activity of TGF-ß-sensitive target genes (11) . Besides Smads, other signaling pathways can be activated by the ALK5 kinase including p38 mitogen activated protein kinase (MAPK), which in turn can occur in a Smad-dependent or Smad-independent manner (12) . Due to its potent antiproliferative effects on epithelial cells, TGF-ß is generally viewed as a tumor suppressor.
Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease in which nonsurgical therapy is ineffective and in which the majority of patients harbor metastatic lesions at presentation, precluding the possibility for curative surgical intervention (13) . Treatment of the primary tumor is hampered by its high therapy chemoresistance, the immunosuppressive environment, and a stroma-rich desmoplastic reaction. At the molecular level PDAC is characterized by the presence of mutations in the TGF-ß pathway (40-50% for Smad4, 3-10% for TGFBRII) as well as frequent overexpression of all three isoforms of TGF-ß (14) and Src (15) . In a mouse model of human pancreatic cancer, inactivating mutations in the genes for Smad4 or TßRII in pancreatic duct epithelial cells eventually result in the formation of PDAC (16, 17) . Later in pancreatic tumorigenesis, however, TGF-ß through ALK5 may promote chemoresistance, migration, angiogenesis, tumor cell invasion, and eventually metastasis (8, (18) (19) (20) (21) , explaining its dual role in carcinogenesis through noncanonical TGF-ß signaling pathways such as p38.
Given their overlapping spectra of cellular activities, their causative role in initiation and maintenance of cellular transformation as well as their oncogenic effects during later stages of tumorigenesis, it is not surprising that there is evidence for signaling crosstalk between Src and TGF-ß/ ALK5, e.g., in breast cancer cells (20, 22) . However, whether Src is directly involved in TGF-ß-induced growth control, EMT, and cell migration in PDAC cells has not yet been analysed. This knowledge is crucial to help deciding whether it is feasable to therapeutically target Src and TGF-ß signaling individually or in a combined approach. Previous studies that attempted to inhibit Src's oncogenic functions in vivo often employed the common Src family kinase (SFK) inhibitors PP2 and PP1 (9, 23, 24) . However, we (unpublished data) and others (25) have recently identified PP2 and PP1, respectively, as potent inhibitors of the kinase activity of TßRI and II, complicating the interpretation of in vivo and in vitro data obtained with these agents and raising the possibility that cellular effects ascribed to Src were in fact mediated in part or exclusively by the TGF-ß receptor(s). Consequently, in order to test whether Src and TGF-ß signaling indeed cooperate and to distinguish effects of Src from those of TGF-ß signaling it is mandatory that specific (genetic) inhibition strategies be used. Here, we have used dominant negative (dn), or RNA interference (RNAi), in combination with the relatively specific Src inhibitor SU6656 (26) to suppress Src activity and expression, respectively. We reveal that Src promotes basal growth and antagonizes TGF-ß1-induced growth inhibition while it does not appear to be involved in TGF-ß1-induced EMT in either cell line.
Materials and methods
Antibodies and reagents. The antibodies and their suppliers were: phospho-Src (Tyr418): Biosource (Nivelles, Belgium), v-Src (Ab-1): Merck Biosciences (Darmstadt, Germany), Src (GD11): Upstate Biotechnology (via Sigma, Deisenhofen, Germany), p125 FAK (focal adhesion kinase, FAK), Smad2/3 (E-20), and HSP90: Santa Cruz Biotechnology (Heidelberg, Germany), phospho-Smad2 (Ser465/467), phospho-Smad3 (Ser423/425)/Smad1(Ser463/465), phospho-p38 (Thr180/ Tyr182), and p38: Cell Signaling Technology (via New England Biolabs, Frankfurt, Germany), Smad2: Zymed (Berlin, Germany), ß-actin: Sigma. SU6656 was purchased from Merck Biosciences, and SB431542 from Tocris (Ellisville, MO). Pharmacological inhibitors were added to cells 30-60 min before the addition of TGF-ß1 (R&D Systems, Wiesbaden, Germany) which was used at a concentration of 5 ng/ml. All other reagents used were of analytical grade purity.
Cell culture. Human pancreatic adenocarcinoma Panc-1 and Colo 357 cells were maintained as described earlier (27) . The generation of the HPDE6c7 cell line (a kind gift of M.S. Tsao) is described elsewhere (28, 29) . These cells were cultured in RPMI-1640 medium and K-SFM (PAA Laboratories, Cölbe, Germany) (1:1) supplemented with 0.5% L-glutamine, 50 μg/ml bovine pituitary extract and 5 ng/ml EGF (Invitrogen, Karlsruhe, Germany), 5% fetal calf serum (FCS), 100 μg/ml penicillin/streptomycin (both from Biochrom KG, Berlin, Germany). Panc-1 cells stably transduced with retroviral vector were cultured in the presence of 700 μg/ml geneticin (Invitrogen).
RNA isolation and quantitative real-time RT-PCR analysis.
Total RNA was isolated with PeqGoldRNApure (peqlab, Erlangen, Germany) and reverse-transcribed using SuperScript II reverse transcriptase (Invitrogen). The conditions for quantitative real-time PCR (qPCR) as well as PCR oligonucleotide primer sequences for ß-actin, TATA-box binding protein (TBP) and GAPDH (30) , E-cadherin and Snail2/Slug (31) were described in detail earlier. Real-time PCR was performed on an I-cycler with IQ software (Bio-Rad, München, Germany). All values for E-cadherin and Slug were normalized to those for at least two different housekeeping genes in the same sample to account for small differences in cDNA input.
Construction of vectors and retroviral infection.
A cDNA for dn murine Src (Y416F, K295R, in pUSEamp) was purchased from Upstate Biotechnology (via Biomol, Hamburg, Germany). For retroviral expression of dnSrc, the entire open reading frame was excised with ClaI and PmeI and inserted into the retroviral vector TJBA5bMoLink-neo [TJ-neo (27) ]. Positive clones (evaluated by PCR, restriction analysis and sequencing of the plasmid-cDNA junctions) were cotransfected into 293T producer cells along with retroviral packaging vectors as described previously (27) . Retroviral particles released by 293T cells were used to infect Panc-1 cells. Pools and individual clones of productively infected cells were obtained after selection with geneticin. The dnSrc cDNA was also cloned into pcDNA3 for use in transient transfections. Expression vectors for dn versions of FAK (FRNK, FAK-related nonkinase) and Pyk2 (CRNK, calcium regulated non-kinase) were generated by cDNA amplification with primers FRNK-for (5'-catgaggatggagtccagaagac-3') and FRNK-rev (5'-tcagtgtggt ctcgtctgcc-3'), and CRNK-for (5'-taccatggagaaggacattgc catggag-3') and CRNK-rev (5'-cgtcactctgcaggtgggtg-3'), respectively, and Pfu polymerase (Stratagene, Heidelberg, Germany). The resulting fragments were subcloned in sense orientation into the EcoRV site of pcDNA3 and verified by restriction enzyme analysis and sequencing. Real-time measurement of cell migration. Using the xCELLigence RTCA DP device from Roche Diagnostics (Mannheim, Germany) real-time measurements of cell migration on wild-type or transfected Panc-1 and Colo 357 cells were performed. For this purpose, 60,000-90,000 cells were seeded per well in CIM-Plates 16 (Roche Diagnostics). Prior to cell seeding the underside of the wells from the upper chamber was coated with 30 μl of collagen I (Sigma, Deisenhofen, Germany). Collagen I (400 μg/ml) was chosen since it represents the major matrix protein in PDAC tissue. Growth factors (TGF-ß1, EGF) and inhibitors (SB431542, SU6656) were dissolved in culture medium containing 1% FCS added to both lower and upper wells at the same concentration. 3 H]-thymidine-labeled cells were lysed and counted in a ß-counter as described in detail previously (32) Assays were run in the 96-well format with 6-wells processed in parallel for all treatments and controls.
Statistical analysis. Statistical significance was calculated using the unpaired Student's t-test. Data were considered significant at p<0.05.
Results

TGF-ß1 stimulation of Panc-1 cells activates c-Src.
PDAC tissues have been reported to overexpress Src relative to normal pancreatic tissue (15) . To confirm that this is reproduced also at the tumor cell level, we monitored expression of total Src in a series of established PDAC cell lines and in the nontumorigenic human pancreatic ductal epithelial cell line HPDE6c7. Panc-1 and Colo 357, two PDAC cell lines known to have retained TGF-ß responsiveness, as well as HPDE6c7 cells all exhibited moderate to high Src protein levels as determined by immunoblot analysis (Fig. 1A) . All further experimentation on malignant cells was done primarily with Panc-1 cells since a large number of studies on the role of both TGF-ß and Src (5, 7, 9, 19) in PDAC tumorigenesis has been performed with this cell line. Next, we tested whether Src can be activated by TGF-ß1 in Panc-1 cells. For this purpose, we determined phosphorylation at Y418, the major autophosphorylation site and marker of Src kinase activation, after various lengths of TGF-ß1 treatment. Src phosphorylation at this site increased in a time-dependent albeit delayed manner peaking at 4 h post TGF-ß1 addition (Fig. 1B) . This indicates that Src is expressed in Panc-1 cells and is susceptible to activation by exogenous TGF-ß1.
Dn Src and Src siRNA both suppress basal proliferation and enhance TGF-ß1-mediated growth arrest. To confirm the role of Src in modifying TGF-ß1-induced growth responses, we generated Panc-1 cells stably expressing dn Src (Y416F, K295R) from a retroviral vector. After selection with geneticin individual clones were shown by immunoblotting to express the Src mutant ( Fig. 2A) . When tested in a [
3 H]-thymidine incorporation assay these clones were found to exhibit strong growth inhibition in both untreated and TGF-ß1-treated cells (Fig. 2B) . Very similar results were obtained when Panc-1 cells (Fig. 2C) or non-tumorigenic pancreatic ductal epithelial HPDE6c7 cells (Fig. 2D) were first transiently transfected with siRNA to Src and subsequently subjected to DNA synthesis measurements in the absence and presence of TGF-ß1. In addition, in Colo 357 cells exposed to SU6656 both basal and TGF-ß1-inhibited DNA synthesis was further reduced (data not shown). The data clearly show that specific inhibition of Src in PDAC cells by lowering its activity (dn Src, SU6656) or expression (siRNA) strongly reduces basal growth and enhances TGF-ß1-induced growth inhibition. We further conclude that these effects of Src were not confined to PDAC cells since they also operate in premalignant HPDE6c7 cells. (33, 34) which has been associated with an invasive phenotype and migratory behavior (33) . To evaluate whether Src was involved in mediating EMT in PDAC cells, we utilized the Panc-1 cells ectopically overexpressing dn Src. Parental Panc-1 cell cultures treated for 48 h with TGF-ß1 presented with a fibroblastoid morphology and long slender processes (Fig. 3A, arrows) , whereas untreated cells were tightly packed and exhibited a cobblestone-like growth pattern. Noteworthy, Panc-1-dn Src cells failed to suppress these morphologic changes upon TGF-ß1 stimulation (Fig. 3A) . Similar data were obtained upon SU6656-mediated Src inhibition in Colo 357 cells (data not shown). We also analysed in TGF-ß1-treated dn Src-expressing and empty vector control Panc-1 cells the EMT marker E-cadherin the transcriptional silencing of which represents a hallmark and causative event in TGF-ß1-induced EMT, and the EMT-associated transcription factor Slug. As expected from the morphology data, stable transfection with dn Src was unable to prevent the TGF-ß1-induced downregulation of E-cadherin and upregulation of Slug as measured by qPCR (Fig. 3B) . Rather, dn inhibition of Src even enhanced both basal and TGF-ß1-controlled E-cadherin mRNA expression (without releaving the inhibitory TGF-ß effect), consistent with an earlier report that activated Src downregulates E-cadherin gene expression in pancreatic cancer cell lines (6). Interestingly, dn Src also potentiated TGF-ß1-induced Slug expression (Fig. 3B) . Together, the data illustrate that Src is dispensable for TGF-ß1-induced EMT in PDAC cells.
Inhibition of Src fails to block TGF
Specific inhibition of Src suppresses both basal and TGF-ß1-induced cell migration.
Prompted by the finding that inhibition of Src was unable to prevent the morphologic and molecular changes associated with TGF-ß1-induced EMT, we asked whether Src would be involved in controlling basal and TGF-ß1-induced cell motility. All cell migration data were acquired with the xCELLigence RTCA DP device, a novel real-timebased cell migration assay which allows for continuous data recording over a period of several days. Moreover, in contrast to endpoint assays like the standard transwell assay this device allows to precisely determine the peak of migratory activity of a given cell population in culture. Panc-1 cells responded to TGF-ß1 stimulation with strongly enhanced cellular migration as determined with the xCELLigence assay (Fig. 4) . Measurement of untreated and TGF-ß1-stimulated Panc-1-dn Src cells (two individual clones) showed that both basal and TGF-ß1-triggered migratory activity was dramatically reduced (Fig. 4A) . Very similar results were obtained following transient transfection of Panc-1 cells with Src siRNA (Fig. 4B) . The migratory response to exogenous TGF-ß1 was ALK5-dependent as concomitant treatment with SB431542 (35) abolished TGF-ß1-induced cell motiliy (Fig. 4C) . Together, these results clearly show that although Src is dispensable for TGF-ß1-induced EMT, it is required for basal and TGF-ß1-induced cell migration in Panc-1 cells.
Src inhibition does not interfere with TGF-ß1-induced RSmad activation but inhibits basal and TGF-ß1-induced p38
MAPK phosphorylation in Panc-1 cells. We have shown above that Src inhibition decreased basal and TGF-ß1-induced cell motility as well as basal proliferation but enhanced TGF-ß1-induced growth arrest. Since both responses require activation of Smad proteins this suggested the possibility that Src signaling interacts with either TGF-ß/Smad and/or non-Smad signaling. To determine whether Src signaling is required for TGF-ß/Smad transcriptional responses, Panc-1 cells were transiently transfected with the Smad-responsive reporter plasmids 3TPlux or p6SBE-luc together with dn mutants of either Src, FAK (FRNK) or the related Pyk2 (CRNK) and subjected to reporter gene assays. Interestingly, dn Src and FRNK but not CRNK partially suppressed the TGF-ß1 effect on both 3TPlux and p6SBE-luc (Fig. 5A) .
To test the possibility that Src inhibits the kinase activity of ALK5, we monitored cytosolic R-Smad activation following TGF-ß1 treatment. C-terminal phosphorylation of Smad2 and Smad3 by TGF-ß1 remained unaffected in Panc-1-dn Src stable clones (Fig. 5B ) and in Panc-1 cells transiently cotransfected with FLAG-tagged-Smad2 and dn Src (not shown). As additional controls, we again employed SU6656 which, was also unable to block Smad2 phosphorylation, while SB431542 effectively abolished it (Fig. 5C ). Total levels of Smad2 and Smad3 always remained unchanged (Fig. 5B and C) . We (30) and others (36) have shown previously that TGF-ß1 activates the p38 MAPK pathway in Panc-1 cells which is involved in K-ras-mediated cell migration in these cells (37) . It was therefore of interest to analyse whether specific Src inhibition affected p38 phosphorylation in these cells. Interestingly, TGF-ß1-mediated phosphorylation of p38 in Panc-1 cells stably expressing dn Src (the same clones as above) was reduced or abolished when compared to empty vector control cells (Fig. 5D) . The data indicate that Src is required for the activation of p38 by TGF-ß1 and, in addition, may partially mediate TGF-ß/ALK5/Smad-induced transcriptional effects at some point downstream of R-Smad activation. Fig. 2A) were resuspended in medium with 1% FCS and seeded into the wells of a CIM-Plate 16 (60,000/well) of the RTCA DP instrument. Cells were allowed to migrate in the presence of TGF-ß1 (5 ng/ml, added to both the lower and upper compartment). Changes in impedance resulting from cells that have migrated to the underside of wells (chemokinesis) were recorded every 15 min and monitored for a total of 48 h. Red curve, untreated vector control cells; green curve, TGF-ß1-treated vector control cells; blue curve, untreated dn Src expressing cells; pink curve, TGF-ß1-treated dn Src expressing cells. (B) Panc-1 cells transfected twice (on days 2 and 3 after seeding) with control and Src-specific siRNAs were trypsinized on day 4 and subjected to RTCA DP assay as described in (A). Red curve, untreated lipofectamine treated cells; green curve, TGF-ß1-treated lipofectamine treated cells; dark blue curve, untreated control siRNA transfected cells; pink curve, TGF-ß1-treated control siRNA transfected cells; turquoise curve, untreated Src siRNA transfected cells; light blue curve, TGF-ß1-treated Src siRNA transfected cells. (C) Effect of the specific ALK5 inhibitor SB431542 on TGF-ß1-induced cell motility. Wild-type Panc-1 cells were processed for the RTCA DP migration assay as described in (A) and allowed to migrate for 48 h in the absence or presence of TGF-ß1 and SB431542 (1 μM). Data in (A-C) were taken from a representative experiment (out of at least three performed in total each with very similar results) and are presented as the mean values ± SD of quadruplicate wells.
Discussion
Both Src and TGF-ß can drive cancer progression by promoting primary tumor growth, angiogenesis, invasion, migration, and metastasis. In PDAC tissues and cell lines Src and TGF-ß1 are overexpressed and Src kinase activity is often increased (15) . Previous in vitro and in vivo studies that have attempted to block the oncogenic activity of Src have mostly employed pharmacologic inhibitors which generally suffer from a lack of specificity (26) . Specifically, PP1 has been shown by Maeda and cowokers (25) to be a powerful inhibitor of TßRI (and TßRII), raising the possibility that effects ascribed to Src were in fact mediated by the TßRs. In this study, we employed tumorigenic Panc-1 (primarily) and Colo 357 cells [two TGF-ß1-responsive cell lines most commonly used as orthotopic xenotransplantation models for preclinical evaluation of anticancer agents in PDAC (23,24)] in conjunction with highly specific genetic inhibition strategies to probe the role of Src in TGF-ß1-mediated cellular responses relevant for PDAC progression. Using these specific inhibition strategies we demonstrate that Src differentially affects TGF-ß1-induced growth arrest, EMT, and cell migration.
In Panc-1 and non-tumorigenic HPDE6c7 cells both stable ectopic expression of dn Src as well as siRNA-mediated knockdown of Src suppressed basal growth which is consistent with the growth-promoting function of Src. Both experimental approaches also increased the cytostatic effect of TGF-ß1 though this effect was more pronounced upon siRNA-mediated silencing of Src (compare panels B and C in Fig. 2) . The reason for this discrepancy is unclear at present but may be related to the higher overall inhibition of the basal proliferative activity by dn Src (probably as a result of its expression in all cells of the culture versus expression of siRNA in only a fraction of cells), or, alternatively, may be explained by a The total p38 levels were visualized with an antibody to p38 (t-p38).
non-kinase-related function(s) of Src that is still preserved in the dn mutant. Nevertheless, the data indicate that Src was not directly involved in mediating growth inhibition by TGF-ß1.
TGF-ß is a well known promoter of EMT but whether Src is involved in this process is still a matter of debate. Since no information in this regard was available for PDAC cells, we analysed whether TGF-ß1-induced EMT was sensitive to inhibition of Src. Ectopic expression of dn Src failed to prevent the morphological and transcriptional changes associated with EMT, suggesting that in PDAC cells Src is dispensable for TGF-ß1-induced EMT. Consistent with this, we have shown that treatment with the Src-specific inhibitor SU6656 had no effect either, while SB431542 and PP1, the latter targeting TßRI and Src, completely prevented the morphological changes associated with TGF-ß1-induced EMT [ (25) (25) demonstrated that Src does not play a role in TGF-ß-induced EMT, Galliher and Schiemann (20) reported that Src promoted it by ß3 integrinmediated induction of TßRII tyrosine phosphorylation, and ERK1/2 and p38 MAPK activation. Likewise, Galliher and Schiemann also found a role for Src in TGF-ß-induced EMT of breast cancer cells (20) . It remains to be seen whether the involvement of Src in EMT is a species-specific, cell type-specific, or context-dependent event, or whether it is even associated with the stage of malignancy within a given tumor entity.
Both dn Src expression and SU6656 treatment failed to suppress Smad2 and Smad3 activation by TGF-ß1 but abolished TGF-ß1-induced activation of p38 MAPK, which suggests a role of Src in the activation of p38 by TGF-ß1. Unlike other cellular functions, dn inhibition of Src and FAK, the latter of which is an Src substrate, moderately albeit significantly reduced TGF-ß1 transcriptional activity on two TGF-ß/Smad-responsive reporters. Together with the positive regulation of the p6SBE-luc reporter by kinase-active Src (Ungefroren et al, unpublished data), these data indicate that in Panc-1 cells Src is partially involved in transcriptional responses to TGF-ß1 downstream of Smad2/3 activation.
Although Src was dispensable for TGF-ß1-induced EMT in both Panc-1 and Colo 357 cells, it clearly enhanced basal migration in Panc-1 cells as observed previously by others (19) and was strictly required for a full TGF-ß1-induced migratory response in Panc-1 cells. Src regulation of TGF-ß1-dependent cell motility in PDAC cells may be mediated through p38 MAPK since p38 is required for TGF-ß-mediated cell migration (38) . Moreover, Src has been shown to regulate TGF-ß stimulation of p38 MAPK during invasion and proliferation of breast cancer cells (39) . However, in Panc-1 cells activation of p38 is not required for TGF-ß1-mediated growth arrest (Ungefroren et al, unpublished data), providing an explanation for the differential effect of Src in TGF-ß1 control of cell growth and migration. The slow kinetics of TGF-ß1-triggered Src phosphorylation (peak at 4 h of exposure to TGF-ß1) and cell migration (peak between 30 and 40 h), however, suggested that these were indirect effects and that other receptors known to activate Src, e.g., EGF-R act downstream of TßRI/ALK5 (40) . Crosstalk of TGF-ß signaling with EGF-R signaling is indeed known to occur in Panc-1 cells during TGF-ß control of the cytostatic response (41) . Other possible candidates are G protein-coupled receptors such as PARs (4) as we have obtained preliminary evidence that PAR-2 is required for TGF-ß1/ALK5-mediated cell migration possibly through receptor transactivation.
Taken together, the results of this study establish that in PDAC cells Src promotes basal proliferation as well as basal and TGF-ß1-induced cell migration while it appears to be dispensable for TGF-ß1-mediated growth arrest and EMT. Our results obtained with the use of specific inhibitors might aid in dissociating oncogenic functions exerted by Src from those of the TßRs, the knowledge of which is mandatory for using pharmacologic Src inhibitors in studies of experimental cancer therapeutics of late-stage PDAC.
